AACR: Adding Nivolumab to Neoadjuvant Chemo Slows Resectable NSCLC

TUESDAY, April 12, 2022 -- Neoadjuvant nivolumab plus chemotherapy results in significantly longer event-free survival and increased pathological response among patients with resectable non-small cell lung cancer (NSCLC) compared with chemotherapy...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news